Halozyme Secures $15 Million Upfront for Hypercon License Covering Three Drug Targets
Halozyme’s Hypercon technology was licensed to Vertex for up to three drug targets, earning a $15 million upfront payment plus future milestones and royalties. The Hypercon microparticle platform enables hyperconcentration of biologics to cut injection volume and support at-home administration of next-generation therapies.
1. Collaboration Terms
Halozyme Hypercon entered into a global exclusive license agreement granting Vertex rights to use Hypercon™ technology for up to three specified drug targets. Under the deal, Vertex will pay a $15 million upfront fee and remains responsible for development, regulatory, and commercialization expenses, while Halozyme will receive milestone payments and royalties on net sales.
2. Hypercon™ Technology
Hypercon™ is a microparticle-based hyperconcentration platform designed to increase the concentration of drugs and biologics, enabling equivalent dosing in reduced injection volumes. This technology supports convenient subcutaneous delivery and at-home administration by compressing volume without compromising therapeutic efficacy.
3. Financial and Strategic Impact
The upfront payment boosts Halozyme’s near-term revenue, while potential milestone and royalty streams could enhance long-term earnings. Partnering with Vertex, a leader in transformative therapies for serious diseases, also validates Hypercon’s potential and may attract further collaborations across biopharma programs.